Repligen (NASDAQ:RGEN) Releases Earnings Results, Misses Estimates By $0.01 EPS

Repligen (NASDAQ:RGEN) issued its earnings results on Wednesday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01), Briefing.com reports. The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. During the same quarter in the previous year, the firm posted $0.64 EPS. The firm’s revenue for the quarter was down 17.1% compared to the same quarter last year. Repligen updated its FY24 guidance to $1.42-1.49 EPS and its FY 2024 guidance to 1.420-1.490 EPS.

Repligen Stock Up 0.4 %

NASDAQ RGEN traded up $0.74 during mid-day trading on Friday, reaching $167.05. 454,984 shares of the company’s stock traded hands, compared to its average volume of 538,521. The company has a current ratio of 6.35, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a fifty day simple moving average of $180.81 and a 200-day simple moving average of $173.90. The company has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a P/E/G ratio of 5.44 and a beta of 1.03.

Insider Buying and Selling at Repligen

In other news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 in the last three months. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on RGEN. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday. KeyCorp raised their price objective on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.